Sema4 Holdings Corp - Ordinary Shares - Class A Aktie News

Shares in genetic testing company GeneDx Holdings (WGS 0.74%) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy of Pediatrics' (AAP) updated guidance, which recommends exome and genetic testing as a first-line test for children with global developmental delays (GDDs) and intellectual disabilities (IDs).

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

Marriott Vacations Worldwide director Christian Asmar bought 412,449 shares for just over $27.88 million.

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle Children's supporting the application of rapid exome sequencing (rES) and rapid genome sequencing (rGS) as a first-tier test for non-critical p...

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances because of superior ...

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.

NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ:WGS) on behalf of GeneDx stockholders.